DNDi presented a symposium on human African trypanosomiasis (sleeping sickness), presented new results from an ASMQ clinical study in children, participated in a symposium on Kinetoplastid diseases, and made oral and poster presentations.
DNDi also co-sponsored a side event on Chagas disease.
|
Symposium |
DNDi Symposium: #164
Towards the elimination of human African trypanosomiasis (HAT)
Date: November 5, 2014
Chair: Jose Ramon Franco, WHO
Co-chair: Crispin Lumbala, PNLTHA
| Veerle Lejon, IRD Advances and challenges in current diagnostics for HAT |
| Antoine Tarral, Head of HAT Clinical Program, DNDi New oral treatments for HAT |
| Wilfried Mutombo, Coordinating investigator, Fexinidazole study for HAT, PNLTHA Implementation of studies in remote areas in countries with limited regulatory and ethics experience |
| Jose Ramon Franco Minguell, Department of Control of Neglected Tropical Diseases, WHO How to achieve HAT elimination with current and new tools |
MSF Symposium: #153
Transitioning from Vertical to Horizontal: Challenges In Integrating Diagnosis and Treatment of Kinetoplastid Diseases in Essential Health Services
Date: November 5, 2014
Chair: K. Ritmeijer, MSF Holland
Co-chair: François Chappuis, HUG, Geneva
| Maria Angeles, MSF, Spain The right balance between vertical and horizontal approaches to diagnose and treat kinetoplastid diseases: the MSF experience |
| Crispin Lumbala, Ministry of Health, Kinshasa, DRC Integration of HAT control into primary healthcare and HAT elimination: achievements and challenges in the DRC |
| François Chappuis, HUG, Geneva From a disease-specific to a syndromic diagnostic approach: the cases of visceral leishmaniasis and human African trypanosomiasis |
| Nathalie Strub-Wourgaft, Medical Director, DNDi New kinetoplastid diseases treatment that can be easily delivered in rural health posts: when will they be available? |
| Oral Presentation |
Efficacy, Safety and Population Pharmacokinetics of the Artesunate Mefloquine (ASMQ) Fixed Dose Combination versus Artemether Lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in African children
Date: November 4, 2014
Scientific Session 64: Malaria: Drug Development – New Approaches, Efficacy, Safety and Pharmacology
Sodiomon Sirima1, Bernhards Ogutu2, John Lusingu3, Ali Mtoro4, Zakayo Mrango5, Alphonse Ouedraogo1, Jean Baptiste Yaro1, Kevin Omondi Onyango6, Samwel Gesase3, Ernest Mnkande4, James Samwel Ngocho5, Joelle Vanraes7, Nathalie Strub7, Gwenaelle Carn7
1.) Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
2.) The Kenya Medical Research Institute, Kisumu, Kenya
3.) National Institute for Medical Research, Korogwe, United Republic of Tanzania
4.) Ifakara Health Institute, Bagamayo, United Republic of Tanzania
5.) National Institute for Medical Research, Kilosa, United Republic of Tanzania
6.) The Centre for Clinical Research- Kenya Medical Research Institute, Nairobi, Kenya
7.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
Drug discovery and development for the treatment and control of filariasis: repurposing emodepside
Download Presentation
Date: November 4, 2014
Scientific Session 108: Filariasis: Clinical
Sabine Specht 1, Charles MacKenzie1, Coralie Martin1, Simon Townson1, Robert Don2, Achim Hoerauf1, Ivan Scandale2
1.) Institute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
2.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
| Poster Presentations |
The AMFm in Ghana: Factors Associated with Private Retailers: Adherence to the Recommended Retail Price
Download Poster
Date: November 5, 2014
Poster session C
John H. Amuasi*1, Beth Virnig1, Graciela Diap2, The AMFm Independent Evaluation Team3
1.) University of Minnesota School of Public Health, Minneapolis, MN, United States
2.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
3.) Komfo Anokye Teaching Hospital, London School of Hygiene and Tropical Medicine, ICF International, Kumasi, Ghana; London, United Kingdom; Rockville, MD, United States
Oral flubendazole: a potentially useful macrofilaricide
Flubendazole, a potential useful chemotherapeutic agent for treatment and control of filarial infections
Download Poster
Date: November 3, 2014
Poster session A
Charles D. Mackenzie1, Timothy G. Geary2, Sabine Specht3, Maeghan O’Neill2, Kennan Marsh4, Achim Hoerauf3, Ivan Scandale5, Steven Silber6
1.) Michigan State University, East Lansing, MI, United States
2.) McGill University, Quebec, QC, Canada
3.) Medical University, Bonn, Germany
4.) AbbVie, North Chicago, IL, United States
5.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
6.) JRD, Raritan, NJ, United States
|
Chagas Side Event |
Changing the Face of Chagas Disease: Scaling Up Diagnosis, Treatment and R&D for People Living with Chagas Disease in the Americas
November 3, 2014
More information: ASTMH website
Side Event
Changing the Face of Chagas Disease:
Scaling Up Diagnosis, Treatment and R&D for People Living with Chagas Disease in the Americas
On November 3, 2014 the Chagas Coalition presented a panel discussion and reception on radically scaling up diagnosis, treatment and research and development (R&D) for people living with Chagas disease, the leading parasitic killer of the Americas.
Coinciding with the American Society of Tropical Medicine and Hygiene (ASTMH) 63rd Annual Meeting taking place in New Orleans, Louisiana, this complementary side event on November 3 was hosted by the Tulane University School of Public Health and Tropical Medicine and brought together patients, researchers, clinicians, and policymakers to shed light on the treatment and research needs of people living with Chagas disease.
Speakers included:
- Dr Pierre Buekens, Tulane University School of Public Health and Tropical Medicine
- Dr Peter Hotez, Sabin Vaccine Institute/National School of Tropical Medicine at Baylor College of Medicine; Past President, ASTMH
- Dr Isabela Ribeiro, DNDi
- Dr Nines Lima, Médecins Sans Frontières
- Dr Sheba Meymandi, Olive View Medical Center
- Dr Anthony Fiore, Centers for Disease Control and Prevention
- Dr Luis Gerardo Castellanos, Pan American Health Organization
- Maira Gutierrez, Chagas disease patient representative
- Watch video of the event
- Listen to Maira Gutierrez, Chagas disease patient representative
- Download Event Invitation
This event was co-organized by:
Press Releases
[New Orleans, LA, USA – 4 November, 2014]
Artesunate-Mefloquine Fixed-Dose Combination (ASMQ FDC) Proves Safe and Efficacious to Treat Children in Africa with Malaria
Clinical Trial Results Provide Evidence for Introducing This Artemisinin Derivative-based Combination Therapy (ACT) into Africa’s Current Malaria Treatment Arsenal to Help Tackle the Number One Parasitic Killer
Presented today at the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene (ASMTH), results of a multi-centre clinical trial in Africa, launched in 2008, to test the efficacy and tolerability of ASMQ fixed-dose combination (FDC) in children under 5 years of age with uncomplicated falciparum malaria showed that ASMQ FDC is as safe and efficacious as Artemether-Lumefantrine (AL) FDC – Africa’s most widely adopted treatment.
[Français]
[New Orleans, LA, USA – 2 November, 2014]
DNDi Receives USD 60 Million to Fill Research and Development Gaps for Neglected Patients
The Drugs for Neglected Diseases initiative (DNDi) has been awarded USD 60 million by the Bill and Melinda Gates Foundation towards the development of new and effective treatments for patients suffering from neglected tropical diseases in the world’s poorest communities. Announced today by Mr Bill Gates at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in New Orleans, this grant will help fill critical gaps in research and development (R&D) for human African trypanosomiasis (sleeping sickness), filarial diseases (notably onchocerciasis, or river blindness), and visceral leishmaniasis (kala-azar).
